30th Oct 2013 09:27
LONDON (Alliance News) - AstraZeneca PLC said Wednesday that it had begun the Phase III Windward trial programme for potential severe uncontrolled asthma treatment benralizumab.
The treatment is developed by MedImmune, AstraZeneza's biologics research and development arm.
Shares in AstraZeneca were trading up 14.20 pence at 3,326.75 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca